COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Telithromycin in Acute Exacerbation of Chronic Bronchitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00288223
Recruitment Status : Terminated
First Posted : February 7, 2006
Last Update Posted : December 9, 2009
Information provided by:

Brief Summary:

Study objectives:

  • to document the clinical efficacy of telithromycin(800 mg per day for 5 days) at Test Of the Cure (TOC)visit (D12-D19), in acute exacerbation of chronic bronchitis.
  • to assess the long-term clinical efficacy of telithromycin by telephone at D25-D35 (V3)
  • to assess the safety of telithromycin

Condition or disease Intervention/treatment Phase
Bronchitis, Chronic Drug: Telithromycin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 54 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter Non Comparative Phase IV Study on the Safety and Efficacy of Telithromycin 800 mg Per Day for 5 Days in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adults
Study Start Date : January 2006
Actual Primary Completion Date : January 2007
Actual Study Completion Date : January 2007

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Drug: Telithromycin
one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.

Primary Outcome Measures :
  1. Percentage of clinical success (cure + improvement) at TOC visit (D12-19),clinical success at TOC visit in at risk sub-populations, clinical success at follow up visit (D25-35), reinfection rates,discontinuation of treatment rates, compliance [ Time Frame: D12-D19 (efficacy assessment) and D25-D35 (telephone follow-up) ]

Secondary Outcome Measures :
  1. Safety assessment of telithromycin (Safety will be assessed on the basis of serious and non serious adverse events) [ Time Frame: At V3 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Outpatients,
  • With a documented history of chronic bronchitis defined by one expectoration daily for at least three consecutive months over at least two consecutive years
  • Presenting with an evident acute exacerbation of their disease defined by the presence of at least two of Anthonisen's criteria:

    • exacerbation of dyspnea,
    • increase in the expectoration volume,
    • increase in the expectoration purulence,

Exclusion Criteria:

  • Acute bronchitis,
  • Chronic obstructive pulmonary disease, those having FEV1 value <35% (FEV1: Forced Expiratory Volume in 1 second)
  • Suspected pneumonia or bronchial pneumonia,
  • Paroxysmal asthma or continuous dyspnea in asthma,
  • Cystic fibrosis,
  • Active tuberculosis,
  • Lung cancer or lung metastasis,
  • Severe bronchiectasia,
  • Acute respiratory decompensation,
  • Chronic respiratory insufficiency associated with resting hypoxemia,
  • Patients requiring hospitalization for parenteral antibiotic treatment
  • Patients with suspected or known bacterial infection other than study diseases, as well as associated systemic or intra-tracheal antibiotic treatment other than study treatment,
  • Participating in another clinical study with any product within 30 days before the inclusion of study
  • Known immunosuppression (AIDS and/or CD4+ lymphocytes < 200/mm3, neutropenia <1500/mm3, blood diseases or terminal stage cancer)
  • Cardiovasculary, neurologic or other severe diseases interfering with the compliance with study protocol or confusing with results.

Conditions associated with study medications:

  • Hypersensitivity against telithromycin , macrolides or any of the excipients,
  • Congenital long QT syndrome or family history of congenital long QT syndrome (this possibility should be excluded with normal ECG) or known acquired QT interval prolongation,
  • Treatment with CYP3A4 inducers (rifampicin, carbamazepine, phenytoin, phenobarbital, St-John's-wort) within 2 weeks prior to the study inclusion
  • Possibility of treatment with ergot alkaloid derivatives, terfenadine, astemizole, pimozide, cisapride, simvastatin, athorvastatin or lovastatin during studies
  • Congenital galactosemia, lactase deficiency glucose or galactose malabsorption syndrome,
  • Pregnant or lactating women,
  • Women with childbearing potential (e.g. ovulating, pre-menopausal or not surgically sterilized) and do not employ any effective contraception method The patients may not participate to the study more than once. The patients who were treated with study drugs previously may not participate to the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00288223

Layout table for location information
Istanbul, Turkey
Sponsors and Collaborators
Layout table for investigator information
Study Director: Edibe Taylan Sanofi
Layout table for additonal information
Responsible Party: Medical Affairs Study Director, sanofi-aventis Identifier: NCT00288223    
Other Study ID Numbers: HMR3647A_4022
First Posted: February 7, 2006    Key Record Dates
Last Update Posted: December 9, 2009
Last Verified: December 2009
Additional relevant MeSH terms:
Layout table for MeSH terms
Bronchitis, Chronic
Acute Disease
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Infections
Disease Attributes
Pathologic Processes
Pulmonary Disease, Chronic Obstructive
Anti-Bacterial Agents
Anti-Infective Agents